---
title: "CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial  | CERO Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285939883.md"
description: "CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial | CERO Stock News"
datetime: "2026-05-11T04:15:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285939883.md)
  - [en](https://longbridge.com/en/news/285939883.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285939883.md)
---

# CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial  | CERO Stock News

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial | CERO Stock News

### Related Stocks

- [CERO.US](https://longbridge.com/en/quote/CERO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [CEROW.US](https://longbridge.com/en/quote/CEROW.US.md)

## Related News & Research

- [Cero Therapeutics Secures $2.09M 10% Convertible Note With SRX Global, Maturing May 2027](https://longbridge.com/en/news/293073319.md)
- [iBio Advances to Clinical Stage With IBIO-600 Trial](https://longbridge.com/en/news/282052903.md)
- [Patient enrolment concludes in Alebund’s Phase III trial of AP301](https://longbridge.com/en/news/285669549.md)
- [Cero Therapeutics amends SRX Health promissory note, lifts borrowing capacity to $1.41 million](https://longbridge.com/en/news/291002769.md)
- [BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials](https://longbridge.com/en/news/285765400.md)